A Study Evaluating the Safety and Tolerability of QRL-201 in ALS

Inclusion Criteria: Male or female participants aged 18 to 80 years diagnosed with ALS ALS symptom onset within 24 months of Screening Slow vital capacity >50% Clinical evidence of lower motor neuron involvement Not pregnant and not nursing Willing and able to practice effective contraception Able to tolerate lumbar puncture If on approved therapies for the treatment of ALS during the course of the study, must be on a stable dose (at the Sponsor's discretion) Exclusion Criteria: Pathogenic variant, likely pathogenic variant, or variant of uncertain significance in the superoxide dismutase 1 (SOD1) and/or fused in sarcoma (FUS) genes Currently enrolled in any other clinical study involving either an investigational product (IP) or off-label use of a drug or device Prior exposure to stem cell or gene therapy products Any contraindication to intrathecal drug administration Abnormal laboratory values deemed clinically significant by the Investigator Significant infection, or known inflammatory process